JP Morgan Maintains Neutral on Progyny, Raises Price Target to $30
JP Morgan analyst Lisa Gill maintains Progyny (NASDAQ:PGNY) with a Neutral and raises the price target from $27 to $30.
Stocks · News reference
Top 3 Health Care Stocks That May Implode This Month
Warning: RSI is above 70 for 3 overbought stocks in healthcare. Progyny, 10X Genomics, and Privia Health have high RSI values and strong price action.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Initiates Coverage On Progyny with Overweight Rating, Announces Price Target of $37
Wells Fargo analyst Stan Berenshteyn initiates coverage on Progyny (NASDAQ:PGNY) with a Overweight rating and announces Price Target of $37.
Truist Securities Maintains Buy on Progyny, Raises Price Target to $36
Truist Securities analyst Jailendra Singh maintains Progyny (NASDAQ:PGNY) with a Buy and raises the price target from $33 to $36.
Barclays Maintains Equal-Weight on Progyny, Lowers Price Target to $30
Barclays analyst Peter Warendorf maintains Progyny (NASDAQ:PGNY) with a Equal-Weight and lowers the price target from $34 to $30.
8-K filing — Privia Health Group, Inc. (PRVA)
Filed: 2026-08-18 AccNo: 0001759655-26-000068 Size: 172 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Privia Health Group shares are trading lower. The company affirmed its FY26 sales guidance with its midpoint below estimates.